J&J's ambitious plan: 10 new potential blockbusters filed by 2019
- In a meeting with industry analysts, Janssen/J&J announced plans to file for approval of 10 new potential 'blockbuster' drugs between 2015 and 2019.
- The company said that it would focus on its five core therapeutic areas, including: Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism and Oncology.
- The company attributes its strong portfolio to a focused R&D strategy.
Even in the era of M&A madness, most of J&J/Janssen's growth is organic, driven largely by R&D-driven expansion.
Janssen's late-stage pipeline includes treatments for uroethelial cancer, multiple sclerosis, rheumatoid arthritis, psoriasis, prostate cancer, refractory depression, osteoarthritic pain, hepatitis C, multiple myeloma, and other conditions. Many of these drugs have received special designations that will help expedite their progress through the regulatory process.
According to J&J, the outlook is especially bright for each of its candidates, with potential earnings of at least $1 billion in each case. That's 10 blockbuster hopefuls over four years.